Anaplastic large-cell lymphoma

Seminars in Diagnostic Pathology

Volumn 28, Issue 3, 2011, Pages 190-201

  Inghirami, Giorgio ^a,b   Pileri, Stefano A ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Anaplastic large cell lymphoma (ALCL); Anaplastic lymphoma kinase (ALK); Chimeric fusion proteins; Immunohistochemistry; Molecular biology; Peripheral T cell lymphoma (PTCL); Phenotype; Signaling pathways; Targeted therapy

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; AP 26113; ARRY 162; CEP 28122; CRIZOTINIB; CYCLOPHOSPHAMIDE; DASATINIB; DOXORUBICIN; MK 2206; PERIFOSINE; PREDNISONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RIDAFOROLIMUS; SARACATINIB; SELUMETINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VINCRISTINE; XL 228;

ARTICLE; CANCER CLASSIFICATION; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; COMPARATIVE GENOMIC HYBRIDIZATION; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; DRUG RESPONSE; DRUG SELECTIVITY; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MALIGNANT TRANSFORMATION; MOLECULARLY TARGETED THERAPY; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC;

EID: 79960146011     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2011.03.002     Document Type: Article

References (99)

1. Stein H., Mason D.Y., Gerdes J., et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985, 66:848-858.
2. Kadin M.E., Sako D., Berliner N., et al. Childhood Ki-1 lymphoma presenting with skin lesions and peripheral lymphadenopathy. Blood 1986, 68:1042-1049.
3. Stansfeld A.G., Diebold J., Noel H., et al. Updated Kiel classification for lymphomas. Lancet 1988, 1:292-293.
4. Harris N.L., Jaffe E.S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392.
5. Rüdiger T., Jaffe E.S., Delsol G., et al. Workshop report on Hodgkin's disease and related diseases ("grey zone" lymphoma). Ann Oncol 1998, 9(suppl 5):S31-S38.
6. Stein H., Warnke R.A., Chan W.C., et al. Diffuse large B-cell lymphoma, not otherwise specified. Tumors of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumors 2008, Vol 4. IARC Press, Lyon, France. S.H. Swerdlow (Ed.).
7. Morris S.W., Kirstein M.N., Valentine M.B., et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994, 263:1281-1284.
8. Delsol G., Gascoyne R.D. ALK-positive large B-cell lymphoma 2008, Stylus Publishing, LLC, Sterling, VA. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
9. Swerdlow S.H., Campo E., Harris N.L., et al. WHO Classification of tumors of hematopoietic and lymphoid tissues 2008, IARC, Lyon. (ed 4).
10. Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 2008, 26:4124-4130.
11. Mason D.Y., Harris N.L., Delsol G., et al. Anaplastic large cell lymphoma (ALCL), ALK-negative. WHO Classification of tumors of hematopoietic and lymphoid tissues 2008, 317-319. IARC, Lyon. (4 ed).
12. Falini B., Pileri S., Zinzani P.L., et al. ALK+ lymphoma: Clinico-pathological findings and outcome. Blood 1999, 93:2697-2706.
13. Stein H., Foss H.D., Dürkop H., et al. CD30(+) anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Blood 2000, 96:3681-3695.
14. Savage K.J., Harris N.L., Vose J.M., et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008, 111:5496-5504.
15. Fraga M., Brousset P., Schlaifer D., et al. Bone marrow involvement in anaplastic large cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic significance. Am J Clin Pathol 1995, 103:82-89.
16. Tilly H., Gaulard P., Lepage E., et al. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood 1997, 90:3727-3734.
17. ten Berge R.L., de Bruin P.C., Oudejans J.J., et al. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology 2003, 43:462-469.
18. Shiota M., Nakamura S., Ichinohasama R., et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 1995, 86:1954-1960.
19. Gascoyne R.D., Aoun P., Wu D., et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999, 93:3913-3921.
20. Falini B., Pulford K., Pucciarini A., et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood 1999, 94:3509-3515.
21. Benharroch D., Meguerian-Bedoyan Z., Lamant L., et al. ALK-positive lymphoma: A single disease with a broad spectrum of morphology. Blood 1998, 91:2076-2084.
22. Jaffe E.S. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol 2001, 14:219-228.
23. Kinney M.C., Collins R.D., Greer J.P., et al. A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. Am J Surg Pathol 1993, 17:859-868.
24. Pittaluga S., Wlodarska I., Pulford K., et al. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am J Pathol 1997, 151:343-351.
25. Delsol G., Jaffe E.S., Falini B., et al. Anaplastic large cell lymphoma (ALCL), ALK-positive. WHO Classification of tumors of hematopoietic and lymphoid tissues 2008, 312-316. IARC, Lyon. (4 ed).
26. Falini B., Pileri S., Pizzolo G., et al. CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995, 85:1-14.
27. Delsol G., Al Saati T., Gatter K.C., et al. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol 1988, 130:59-70.
28. Foss H.D., Anagnostopoulos I., Araujo I., et al. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 1996, 88:4005-4011.
29. Krenacs L., Wellmann A., Sorbara L., et al. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: Evidence for distinct cellular origin. Blood 1997, 89:980-989.
30. Agostinelli C., Sabattini E., Gjørret J.O., et al. Characterization of a new monoclonal antibody against PAX5/BASP in 1525 paraffin-embedded human and animal tissue samples. Appl Immunohistochem Mol Morphol 2010, 18:561-572.
31. Barry T.S., Jaffe E.S., Sorbara L., et al. Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol 2003, 27:1513-1522.
32. Gorczyca W., Tsang P., Liu Z., et al. CD30-positive T-cell lymphomas co-expressing CD15: An immunohistochemical analysis. Int J Oncol 2003, 22:319-324.
33. Voena C., Conte C., Ambrogio C., et al. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res 2007, 67:4278-4286.
34. Piva R., Pellegrino E., Mattioli M., et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest 2006, 116:3171-3182.
35. Piva R., Agnelli L., Pellegrino E., et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J Clin Oncol 2010, 28:1583-1590.
36. Yee H.T., Ponzoni M., Merson A., et al. Molecular characterization of the t(2;5) (p23; q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease. Blood 1996, 87:1081-1088.
37. Ralfkiaer E., Willemze R., Paulli M., et al. Primary cutaneous CD30-positive T-cell lymphoproliferative disorders. WHO Classification of tumors of hematopoietic and lymphoid tissues 2008, 300-301. IARC, Lyon. (4 ed).
38. Falini B., Mason D.Y. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: Clinical value of their detection by immunocytochemistry. Blood 2002, 99:409-426.
39. Chiarle R., Voena C., Ambrogio C., et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008, 8:11-23.
40. Falini B, Martelli MP, Tiacci E, et al: Immunohistochemical surrogates for genetic alterations of CCDN1, PML, ALK, and NPM1 genes in lymphomas and acute myeloid leukemia. Best Pract Res Clin Haematol 23:417-431.
41. Delsol G., Lamant L., Mariamé B., et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 1997, 89:1483-1490.
42. Gascoyne R.D., Lamant L., Martin-Subero J.I., et al. ALK-positive diffuse large B-cell lymphoma is associated with clathrin-ALK rearrangements: report of 6 cases. Blood 2003, 102:2568-2573.
43. Van Roosbroeck K., Cools J., Dierickx D., et al. ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica 2010, 95:509-513.
44. Pulford K., Morris S.W., Mason D.Y. Anaplastic lymphoma kinase proteins and malignancy. Curr Opin Hematol 2001, 8:231-236.
45. Lamant L., Dastugue N., Pulford K., et al. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 1999, 93:3088-3095.
46. Hernández L., Beà S., Bellosillo B., et al. Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: Identification of a new TFG-ALK(XL) chimeric gene with transforming activity. Am J Pathol 2002, 160:1487-1494.
47. Hernández L., Pinyol M., Hernández S., et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 1999, 94:3265-3268.
48. Colleoni G.W., Bridge J.A., Garicochea B., et al. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv2)(p23q35). Am J Pathol 2000, 156:781-789.
49. Touriol C., Greenland C., Lamant L., et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 2000, 95:3204-3207.
50. Tort F., Pinyol M., Pulford K., et al. Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab Invest 2001, 81:419-426.
51. Cools J., Wlodarska I., Somers R., et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2002, 34:354-362.
52. Lamant L., Gascoyne R.D., Duplantier M.M., et al. Non-muscle myosin heavy chain (MYH9): A new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer 2003, 37:427-432.
53. Gogusev J., Telvi L., Nezelof C. Molecular cytogenetic aberrations in CD30+ anaplastic large cell lymphoma cell lines. Cancer Genet Cytogenet 2002, 138:95-101.
54. Fadlelmola F.M., Zhou M., de Leeuw R.J., et al. Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin lymphoma and anaplastic large cell lymphoma cell lines. Mol Cancer 2008, 7:2.
55. Ott G., Katzenberger T., Siebert R., et al. Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: Infrequent detection of the t(2;5) in extranodal lymphomas. Genes Chromosomes Cancer 1998, 22:114-121.
56. Zettl A., Rüdiger T., Konrad M.A., et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol 2004, 164:1837-1848.
57. Salaverria I., Beà S., Lopez-Guillermo A., et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol 2008, 140:516-526.
58. Feldman EJ: Too much ara-C? Not enough daunorubicin? Blood 117:2299-2300.
59. Kuefer M.U., Look A.T., Pulford K., et al. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 1997, 90:2901-2910.
60. Turner S.D., Alexander D.R. What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis?. Leukemia 2005, 19:1128-1134.
61. Chiarle R., Gong J.Z., Guasparri I., et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 2003, 101:1919-1927.
62. Bischof D., Pulford K., Mason D.Y., et al. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 1997, 17:2312-2325.
63. Mason D.Y., Pulford K.A., Bischof D., et al. Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation. Cancer Res 1998, 58:1057-1062.
64. Bai R.Y., Dieter P., Peschel C., et al. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 1998, 18:6951-6961.
65. Fujimoto J., Shiota M., Iwahara T., et al. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci U S A 1996, 93:4181-4186.
66. Watanabe M., Sasaki M., Itoh K., et al. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and Reed-Sternberg cells of Hodgkin lymphoma. Cancer Res 2005, 65:7628-7634.
67. Hsu F.Y., Johnston P.B., Burke K.A., et al. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner. Cancer Res 2006, 66:9002-9008.
68. Bai R.Y., Ouyang T., Miething C., et al. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 2000, 96:4319-4327.
69. Slupianek A., Nieborowska-Skorska M., Hoser G., et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 2001, 61:2194-2199.
70. Gu T.L., Tothova Z., Scheijen B., et al. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood 2004, 103:4622-4629.
71. Zamo A., Chiarle R., Piva R., et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002, 21:1038-1047.
72. Zhang Q., Raghunath P.N., Xue L., et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 2002, 168:466-474.
73. Chiarle R., Simmons W.J., Cai H., et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005, 11:623-629.
74. Levy D.E., Lee C.K. What does Stat3 do?. J Clin Invest 2002, 109:1143-1148.
75. Inghirami G., Chiarle R., Simmons W.J., et al. New and old functions of STAT3: A pivotal target for individualized treatment of cancer. Cell Cycle 2005, 4:1131-1133.
76. Amin H.M., Medeiros L.J., Ma Y., et al. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 2003, 22:5399-5407.
77. Ambrogio C., Voena C., Manazza A.D., et al. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res 2008, 68:8899-8907.
78. Colomba A., Courilleau D., Ramel D., et al. Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas. Oncogene 2008, 27:2728-2736.
79. Cussac D., Greenland C., Roche S., et al. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 2004, 103:1464-1471.
80. Thompson M.A., Stumph J., Henrickson S.E., et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum Pathol 2005, 36:494-504.
81. Lamant L., de Reyniès A., Duplantier M.M., et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 2007, 109:2156-2164.
82. Eckerle S., Brune V., Döring C., et al. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia 2009, 23:2129-2138.
83. Blystad A.K., Torlakovic E., Holte H., et al. CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HD. Cytotherapy 2001, 3:295-305.
84. Corradini P., Tarella C., Zallio F., et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006, 20:1533-1538.
85. Rodríguez J., Caballero M.D., Gutiérrez A., et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003, 14:1768-1775.
86. Gambacorti-Passerini C., Messa C., Pogliani E.M. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 2011, 364:775-776.
87. Pulford K., Falini B., Banham A.H., et al. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood 2000, 96:1605-1607.
88. Passoni L., Longo L., Collini P., et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res 2009, 69:7338-7346.
89. Ait-Tahar K., Cerundolo V., Banham A.H., et al. B and CTL responses to the ALK protein in patients with ALK-positive ALCL. Int J Cancer 2006, 118:688-695.
90. Ait-Tahar K., Barnardo M.C., Pulford K. CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma. Cancer Res 2007, 67:1898-1901.
91. Passoni L., Gambacorti-Passerini C. ALK a novel lymphoma-associated tumor antigen for vaccination strategies. Leuk Lymphoma 2003, 44:1675-1681.
92. Chiarle R., Martinengo C., Mastini C., et al. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med 2008, 14:676-680.
93. Wan W., Albom M.S., Lu L., et al. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood 2006, 107:1617-1623.
94. Galkin A.V., Melnick J.S., Kim S., et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A 2007, 104:270-275.
95. Webb T.R., Slavish J., George R.E., et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 2009, 9:331-356.
96. Cheng M., Ott G.R. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma. Anti Cancer Agents Med Chem 2010, 10:236-249.
97. Forero-Torres A., Leonard J.P., Younes A., et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009, 146:171-179.
98. Ansell S.M., Horwitz S.M., Engert A., et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007, 25:2764-2769.
99. Ho L., Aytac U., Stephens L.C., et al. In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res 2001, 7:2031-2040.